NO20082288L - Monoklonalt anti-ADDL-antistoff og anvendelse derav - Google Patents

Monoklonalt anti-ADDL-antistoff og anvendelse derav

Info

Publication number
NO20082288L
NO20082288L NO20082288A NO20082288A NO20082288L NO 20082288 L NO20082288 L NO 20082288L NO 20082288 A NO20082288 A NO 20082288A NO 20082288 A NO20082288 A NO 20082288A NO 20082288 L NO20082288 L NO 20082288L
Authority
NO
Norway
Prior art keywords
addl
types
antibodies
disease
monoclonal anti
Prior art date
Application number
NO20082288A
Other languages
English (en)
Norwegian (no)
Inventor
Zhiqiang An
William R Strohl
Gene Kinney
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20082288L publication Critical patent/NO20082288L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20082288A 2005-10-21 2008-05-19 Monoklonalt anti-ADDL-antistoff og anvendelse derav NO20082288L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2005381125 2005-10-21
PCT/US2006/040508 WO2007050359A2 (en) 2005-10-21 2006-10-17 Anti-addl monoclonal antibody and use thereof

Publications (1)

Publication Number Publication Date
NO20082288L true NO20082288L (no) 2008-05-19

Family

ID=39671607

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082288A NO20082288L (no) 2005-10-21 2008-05-19 Monoklonalt anti-ADDL-antistoff og anvendelse derav

Country Status (8)

Country Link
EP (1) EP1940466B1 (https=)
JP (1) JP5289963B2 (https=)
CN (1) CN101291692A (https=)
AU (1) AU2006306553B9 (https=)
CA (1) CA2626783A1 (https=)
NO (1) NO20082288L (https=)
RU (1) RU2008120027A (https=)
WO (1) WO2007050359A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US7931899B2 (en) 2007-05-14 2011-04-26 Medtronic, Inc Humanized anti-amyloid beta antibodies
US8323654B2 (en) 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
PL2170389T3 (pl) * 2007-06-12 2015-03-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
RS53174B (sr) 2007-10-05 2014-06-30 Genentech Inc. Upotreba antiamiloidnog beta antitela u slučaju oboljenja oka
EP2222700A2 (en) * 2007-11-27 2010-09-01 Medtronic, Inc. Humanized anti-amyloid beta antibodies
WO2009079566A2 (en) 2007-12-18 2009-06-25 Acumen Pharmaceuticals, Inc. Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production
EP2321338A1 (en) * 2008-08-14 2011-05-18 Merck Sharp & Dohme Corp. Methods for purifying antibodies using protein a affinity chromatography
WO2011070174A1 (en) 2009-12-11 2011-06-16 Araclon Biotech, S.L. Methods and reagents for improved detection of amyloid beta peptides
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
CA2805414C (en) * 2010-07-14 2020-07-07 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
US9320793B2 (en) 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
US9176151B2 (en) 2010-07-14 2015-11-03 Acumen Pharmaceuticals, Inc. Antibodies, kit and method for detecting amyloid beta oligomers
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
AU2012282825B2 (en) * 2011-07-13 2016-05-26 Merck Sharp & Dohme Corp. Method for detection of amyloid beta oligomers in a fluid sample and uses thereof
JP6231263B2 (ja) * 2012-07-17 2017-11-15 株式会社島津製作所 アフィニティ支持体及びそれを用いた物質の捕捉方法
EP3166970B1 (en) 2014-07-10 2021-03-10 BioArctic AB Improved a-beta protofibril binding antibodies
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
WO2021055670A1 (en) 2019-09-20 2021-03-25 Avx Corporation Somatic cell-based electrical biosensor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0683234B2 (en) * 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
EP2006303A1 (en) * 1997-04-09 2008-12-24 Intellect Neurosciences, Inc. Recombinant antibodies specific for Beta-Amyloid ends, DNA encoding and methods of use thereof
WO2004031400A2 (en) * 2002-10-01 2004-04-15 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
PE20050627A1 (es) * 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US7780963B2 (en) * 2004-10-25 2010-08-24 Merck & Co., Inc. Anti-ADDL antibodies and uses thereof

Also Published As

Publication number Publication date
EP1940466B1 (en) 2012-11-28
JP2009519895A (ja) 2009-05-21
WO2007050359A2 (en) 2007-05-03
JP5289963B2 (ja) 2013-09-11
AU2006306553B2 (en) 2011-08-25
CA2626783A1 (en) 2007-05-03
WO2007050359A8 (en) 2008-05-08
CN101291692A (zh) 2008-10-22
WO2007050359A3 (en) 2007-06-21
RU2008120027A (ru) 2009-11-27
EP1940466A4 (en) 2010-04-07
EP1940466A2 (en) 2008-07-09
AU2006306553B9 (en) 2011-09-29
AU2006306553A1 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
NO20082288L (no) Monoklonalt anti-ADDL-antistoff og anvendelse derav
NO20072700L (no) Anti-ADDL antistoffer og anvendelser derav
MX2022005782A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos.
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
WO2012045882A3 (en) Phosphospecific antibodies recognising tau
WO2012009442A3 (en) Anti-addl monoclonal antibody and uses thereof
WO2010115843A3 (en) Pharmaceutical composition
MA45655A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
LUC00053I2 (fr) Anticorps diriges contre cd38 pour le traitement du myelome multiple
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
WO2006099698A3 (en) Novel anti-plgf antibody
AR083819A1 (es) UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL
DE60336848D1 (de) Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz
NO20076021L (no) Antistoffer rettet mot amyloid-betapeptid og metoder som anvender de samme
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
NZ596409A (en) Anti macrophage migration inhibitory factor antibodies
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
WO2006014638A3 (en) ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
Bobkova et al. Immunization with either prion protein fragment 95–123 or the fragment-specific antibodies rescue memory loss and neurodegenerative phenotype of neurons in olfactory bulbectomized mice
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo
WO2014159244A3 (en) O-GlcNAc TAU ANTIBODY AND USE THEREOF
EP1896588A4 (en) NEW A-BINDING PROTEIN AND ITS PEPTIDE DERIVATIVES AND USES THEREOF
WO2010024927A3 (en) Treatment of amyloidoses using myelin basic protein and fragments thereof
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application